[DOI] [PMC free article] [PubMed] [Google Scholar] Eicken C
Demonstrated Safety and Tolerability Profile 1 With RADICAVA , the most common adverse reactions were contusion, gait disturbance, and headache 1, a (see footnote) Safety profile was demonstrated in pooled placebo-controlled trials b (see footnote) in which 184 patients with ALS were administered RADICAVA (edaravone) (60 mg) in 24-week treatment cycles
it's essential for preserving potency
In some embodiments, an otic composition or formulation disclosed herein comprises less than about 5 ppm of each of alcohols, propylene glycol, and cyclohexane
Without that confidence, you're just guessing
Overall, multiple mechanisms including inflammation and reduced FA re-esterification likely explain the impaired buffering capacity in adipocytes during obesity that leads to the spillover of FAs, buildup of toxic lipid metabolites and allosteric regulators that suppress insulin action and increased hepatic glucose output, respectively (Figure 5)